Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL6136 Target Snapshot

Lysine-specific histone demethylase 1A · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
5,864Compounds
955Assays
13Approved Drugs
10,605.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Lysine-specific histone demethylase 1A shows late clinical disease relevance led by essential thrombocythemia. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt O60341. Start with essential thrombocythemia, then reuse UniProt O60341 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with essential thrombocythemia, then reuse UniProt O60341 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 1 linked drug
Open source guide
Disease program
essential thrombocythemia

Lysine-specific histone demethylase 1A shows late clinical disease relevance led by essential thrombocythemia. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with essential thrombocythemia because it currently carries late clinical support. Linked drugs include BOMEDEMSTAT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Late clinical Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Lysine-specific histone demethylase 1A as ChEMBL target CHEMBL6136, mapped to UniProt O60341. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Lysine-specific histone demethylase 1A
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL6136
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
O60341
Lysine-specific histone demethylase 1A
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Lysine-specific histone demethylase 1A is the right protein anchor across sources, using UniProt O60341 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why essential thrombocythemia is currently framed as late clinical support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameLysine-specific histone demethylase 1A
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtO60341
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelLysine-specific histone demethylase 1A
UniProt AccessionO60341
Component TypeProtein
Sequence Length852 aa

Lysine-specific histone demethylase 1A

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Lysine-specific histone demethylase 1A, mapped to UniProt O60341. Sequence length is 852 aa.

Mapped IDO60341
Review nameLysine-specific histone demethylase 1A
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Late clinical Open Targets-ready proxy

Lysine-specific histone demethylase 1A shows late clinical disease relevance led by essential thrombocythemia. 5 more disease programs remain visible in the same review block.

Late clinical Phase III
essential thrombocythemia
1 linked drug · 1 direct · 1 efficacy
Linked drugBOMEDEMSTAT
Clinical signal Phase II
myelofibrosis
1 linked drug · 1 direct · 1 efficacy
Linked drugBOMEDEMSTAT
Clinical signal Phase II
polycythemia vera
1 linked drug · 1 direct · 1 efficacy
Linked drugBOMEDEMSTAT
Clinical signal Phase I
acute myeloid leukemia
1 linked drug · 1 direct · 1 efficacy
Linked drugBOMEDEMSTAT
Clinical signal Phase I
myelodysplastic syndrome
1 linked drug · 1 direct · 1 efficacy
Linked drugBOMEDEMSTAT
Clinical signal Phase I
neoplasm
1 linked drug · 1 direct · 1 efficacy
Linked drugBOMEDEMSTAT
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with essential thrombocythemia because it currently carries late clinical support. Linked drugs include BOMEDEMSTAT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseessential thrombocythemia
Strongest levelLate clinical
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

13
Approved
9
Phase III
13
Phase II
5
Phase I
1
Phase 0.5
Assay Mix

Activity Type Distribution

IC509,921.0
KI518.0
EC5062.0
KD104.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL4798849 10.3 IC50 0.05 Preclinical
CHEMBL5970037 10.22 IC50 0.06 Preclinical
CHEMBL4762799 10.22 IC50 0.06 Preclinical
CHEMBL6002210 10.21 IC50 0.062 Preclinical
CHEMBL5767321 10.15 IC50 0.07 Preclinical
CHEMBL6032207 10.12 IC50 0.075 Preclinical
CHEMBL6012501 10.12 IC50 0.076 Preclinical
CHEMBL5855787 10.05 IC50 0.09 Preclinical
CHEMBL5822088 10.04 IC50 0.091 Preclinical
CHEMBL5942048 10.03 IC50 0.093 Preclinical
Distribution

pChEMBL Value Distribution

491
5.0
465
5.5
836
6.0
1191
6.5
859
7.0
672
7.5
294
8.0
167
8.5
170
9.0
131
9.5
pChEMBL
Approved Drugs

Approved Drugs

CAPSAICIN
CHEMBL294199
Approved 2009
Properties Compare Identifier
FENOLDOPAM
CHEMBL588
Approved 1997
Properties Compare Identifier
AMSACRINE
CHEMBL43
Approved 1987
Properties Compare Identifier
TRANYLCYPROMINE
CHEMBL3989843
Approved 1961
Properties Compare Identifier
Assay Landscape

Assay Landscape

955
Total Assays
4,188
Tested Compounds
3
Assay Types
Binding — 945 assays, 4,188 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 424 474 6.5
single protein format 367 2,897 6.9
assay format 149 813 5.9
subcellular format 2 0 —
tissue-based format 2 1 5.7
organism-based format 1 3 6.9
ADME — 7 assays, 1 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 7 1 5.4
Functional — 3 assays, 2 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 3 2 8.9

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine